InvestorsHub Logo
Followers 67
Posts 16221
Boards Moderated 2
Alias Born 02/14/2011

Re: None

Wednesday, 06/27/2012 10:32:05 AM

Wednesday, June 27, 2012 10:32:05 AM

Post# of 110
12:02 PM Medivation (MDVN +1.2%) moves up on positive comments out of William Blair this morning. The firm raised its selling price estimate for the company's prostate cancer treatment enzalutamide, based on what it sees as superior data compared with its competitors. The firm maintains an Outperform rating and raises its price target to $119 from $96